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INTRODUCTION
Artemisinin-based combination therapy (ACT),
namely artesunate + sulphadoxine-pyrimethamine
(AS+SP) is the first-line treatment for the uncomplicated
Plasmodium falciparum malaria episodes throughout
India1. The urgency for ACT roll-out was spurred by
alarming levels of drug resistance to previously used
monotherapies such as chloroquine (CQ) and
sulphadoxine-pyrimethamine (SP) and rising morbidity
and mortality2. India switched to ACT in 2005 in chloro-
quine resistant areas of the country, expanding ACT to
more areas with >10% treatment failure in 2007 and later
in 2008, ACT was adopted in 117 districts within the coun-
try, including Jharkhand3. In 2007, four districts of
Jharkhand were identified as chloroquine resistant and
later in 2008 this was expanded to 12 districts which were
notified as chloroquine resistant3. The ACT recommended
in the National Programme of India for chloroquine re-
sistant areas was artesunate (4 mg/kg body weight) daily
for 3-days and sulphadoxine (25 mg/kg body weight),
pyrimethamine (1.25 mg/kg body weight) on Day 0 which
was recommended to be given only to confirmed P.
falciparum cases found positive by microscopy or RDK.
Recommendations were also given for concomitant use
of single dose of primaquine (0.75 mg/kg body weight)
for effective gametocyte clearance thereby interrupting
transmission4.
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ABSTRACT
Background & objectives: Widespread resistance to chloroquine was the mainstay to implement artemisinin-
based combination therapy (ACT) in the year 2007 in few malaria endemic states in India including Jharkhand as
the first line of treatment for uncomplicated Plasmodium falciparum malaria. This study was conducted in Jharkhand
state of the country just after the implementation of ACT to assess the prevailing antimalarial drug prescribing
practices, availability of antimalarial drugs and the acceptability of the new policy by the health professionals for
the treatment of uncomplicated P. falciparum malaria patients particularly in children ≤15 yr of age.
Methods: This is a cross-sectional study in children aged ≤15 yr with malaria or to whom antimalarial drug was
prescribed. Main outcome measure was prescription of recommended ACT in children aged ≤15 yr with malaria
in the selected areas of Jharkhand.
Results: In the year 2008, artemisinin-based combination therapy (ACT) was implemented in 12 districts of the
studied state; however, the availability of ACT was confirmed only in five districts. Antimalarial prescription was
prevalent amongst the undiagnosed (8.4%), malaria negative (64.3%) and unknown blood test result (1.2%)
suggesting the prevalence of irrational treatment practices. ACT prescription was very low with only 3.2% of
confirmed falciparum malaria patients receiving it while others received either non-artesunate (NA) treatment
(88.1%) including chloroquine (CQ) alone, CQ + Primaquine (PQ)/other drugs, sulphadoxine-pyrimethamine
(SP) alone, SP + other drugs or artemisinin monotherapy (AM) treatment (6.3%). Still others were given non-
antimalarial treatment (NM) in both malaria positive (0.3%) and malaria negative (2.1%) cases.
Interpretation & conclusion: Despite the change in drug policy in the studied state the availability and
implementation of ACT was a major concern. Nevertheless, the non-availability of blister packs for children aged
≤15 yr was the main hindrance in the implementation of the recommended antimalarial. Availability, training and
participation of health professionals in decision-making are the key elements to improve adherence to new treatment
guidelines. This study provided evidence for the requirement of age-specific blister packs in the country and the
national programme has introduced age-specific blister packs in the country in 2010. This baseline information
will be useful to monitor the progress in ACT implementation in the country.
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The introduction of new policy does not get trans-
lated to its implementation immediately at the commu-
nity level5. The key factors behind this may include lack
of prescription by the health workers, its unavailability
with the chemists, lack of production by the industries
thereby affecting sale, lack of compliance by the patients
and general acceptance by the community5. These fac-
tors promote irrational treatment practices and thereby
contribute to the development of drug resistance5.
It has been shown that the dearth in antimalarial drug
supply and malaria diagnostics is the major shortcoming
in effective implementation of the recommended policy and
that the national ministries and the international commu-
nity must address this issue to overcome this problem6–7.
A five year study was conducted in seven malaria endemic
countries to provide evidence to the policy makers on trends
in availability, use and price of antimalarials further high-
lighting the importance of these factors in effective imple-
mentation of the recommended drug policy8. Although
malaria misdiagnosis results from lack of basic infra-
structure and logistics7, there have been reports where im-
proved diagnostics still resulted in inappropriate use of
antimalarials suggesting prevalence of irrational treatment
practices9–14. Despite improved malaria case management,
the issues like policy ambiguities, underuse of diagnostics
and distrust on malaria negative results were still prob-
lems, which resulted in misdiagnosis and incorrect treat-
ments7, 14–16. Furthermore, the task of patient counseling,
improved quality interventions and drug dispensing is
important in malaria case management along with appro-
priate prescription and policy adherence17–20.
The important pre-requisites which help in effective
implementation of malaria case management practices are
availability of recommended, genuine medicines with
discontinued provision of obsolete therapies and the ca-
pacity of the health facility for malaria testing, in general
with the provision of ACTs and diagnostics including a
package of health systems’ support activities for health
workers, in particular, is a necessity21.
In view of this, the present study was carried out to
assess the availability of the recommended antimalarial
and its prescription focusing on the prevalent treatment
practices in children aged ≤15 yr following the change in
drug policy from CQ to ACT (AS+SP) in selected areas
of Jharkhand state of India.
MATERIAL & METHODS
Study site
The study was carried out in Jharkhand state of India.
Information was obtained from the Directorate of the
National Vector Borne Disease Control Programme
(NVBDCP) on districts/areas identified for use of ACT
(AS+SP) for the treatment of P. falciparum malaria. Based
on the above information, districts with the change in drug
policy, where ACT was implemented were identified. In
Jharkhand, ACT was implemented in two stages. In 2007,
four districts in Jharkhand were identified as CQ resistant
(Simdega, Ranchi, Gumla and Saraikela)3. However, in
2008, a total of 12 districts were notified for use of ACT
(AS+SP) for the treatment of P. falciparum malaria3. Sur-
veys were carried out in 2008–09 to obtain information on
the availability of ACT drugs in the notified 12 districts and
in addition, data from state malaria office were also col-
lected on the supply of antimalarial drugs to the above dis-
tricts. As per the records from state programme office, the
availability of ACT was confirmed only in five districts,
namely Gumla, Latehar, Ranchi, Saraikela and Simdega.
Further, in these districts Primary Health Centres (PHCs)
were selected on the basis of availability of ACT drugs
(ACT combi blister pack or loose tablets). A total of 14
PHCs were identified where prescription practices and
compliance with the prescribed drug policy was evaluated.
Besides primary health care facilities, private hospitals,
clinics, missionary hospitals, etc. were surveyed to docu-
ment the prevailing prescription practices. However, the
record keeping and support was inadequate and hence, only
two such facilities were covered.
Study design
Both retrospective and prospective surveillance was
done. The survey involved PHCs with ACT as the first
line of treatment. Retrospective surveillance included
auditing of records which was carried out for a period of
one year from April 2007–March 2008 in selected PHCs
of the studied districts. These cases were children aged
≤15 yr and the criterion for selection of records included
patients to whom antimalarial drugs were prescribed.
Attempt was made to collect data in a large number of
hospitals and PHCs but due to inadequate record mainte-
nance and unavailability of records, surveys were re-
stricted to 14 PHCs in five districts in addition to, two
private health facilities. A total of 6712 records were au-
dited during the study period. Variables recorded include
data on age, sex, signs and symptoms, diagnosis and the
antimalarial medicines prescribed to the patients. The
confidentiality of the data was ensured.
Prospective surveillance was done by exit interviews
of patients attending outpatient department (OPD) in se-
lected PHCs to study the compliance for artemisinin com-
bination drugs in P. falciparum infected children and the
serious adverse events, if any, with the usage of ACT.
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view patients having malaria confirmed either by micros-
copy or by rapid diagnostic kit (RDK) or patients to whom
antimalarial medicine was prescribed. A total of 666
exit interviews were conducted during the study period
(September–October 2009) to ascertain the prevailing pre-
scription practices of antimalarials including ACT in chil-
dren aged ≤15 yr.
Questionnaire design and sample size
The questionnaire was developed with the help of so-
cial scientists, epidemiologists and a statistician. To under-
stand the prevailing prescription practice, audit of prescrip-
tion record of OPD is a useful tool and has been used in a
similar study like this22. Pre-testing of structured performa
in the field was undertaken before initiating the study. A
total of 20 questionnaires for the exit interview of the OPD
patients in the PHC were tested in the field. Sample
size was calculated with the help of senior statistician
from National Institute of Medical Statistics, New Delhi,
India and it was concluded that the audit of one year OPD
record of PHCs with change in drug policy and exit inter-
views from 10% of the OPD load will be appropriate from
each district.
Ethical guidelines
The Scientific Advisory Committee of the National
Institute of Malaria Research approved the study design
and questionnaires. Verbal consent was obtained from
all interviewees, and the data were de-identified. The study
was a public health program evaluation conducted at the
request of WHO representative to India, New Delhi, and
thus IRB exempt.
RESULTS
Availability of ACT drugs
There are a total of 24 districts in Jharkhand state,
out of which 12 were identified as chloroquine resistant
and hence, ACT was implemented in these districts in
2008. However, the supply of ACT was limited to only
five of them, namely Ranchi, Simdega, Saraikela, Latehar
and Gumla. Furthermore, the availability of blister packs
remained confined to only three of them (Ranchi, Latehar
and Simdega). In the other two districts, ACT was avail-
able as loose tablets.
Prescription of antimalarials and use of ACT
Prescription pattern from audit of records: A total
of 6712 records were audited. Details of audit of records
are depicted in Fig. 1. Amongst the diagnosed (16.9%)
cases, which were positive for P. falciparum malaria
(44.4%), ACT prescription was only 4% while others were
Fig. 1: Flow chart of patient case management from audit of records, Jharkhand, India, 2007–08. NA — Non-artesunate treatment; AM—
Artesunate monotherapy; ACT (WHO) or ACT (non-WHO)— Artemisinin-based combination therapy WHO recommended or Artemisinin-
based combination therapy other than WHO recommended; NM—Non-antimalarial. J Vector Borne Dis 50, December 2013 274
given non-artesunate treatment (87.6%), artemisinin
monotherapy (7.6%) and non-antimalarial (0.9%). Plas-
modium vivax cases (54.1%) were given non-artesunate
(97.6%), artesunate monotherapy (1.3%) and non-anti-
malarial (0.8%) treatment. The percentage of undiagnosed
cases was 83.1% in which antimalarial prescription was
prevalent in 94.4% cases while prescription of non-
antimalarial was recorded in 5.6% of cases. There were
others who were given non-WHO ACT (0.2%) which in-
cludes combination of artemisinin derivatives with CQ.
Data were not available for 5.1% of cases in both diag-
nosed (0.4%) and undiagnosed (4.6%) categories.
Prescription pattern from exit interview: A total of
666 exit interviews were conducted in children attending
OPD of the studied PHCs. Two hundred eighty nine exit
interviews were done from the age group 0–5 yr, 219 were
from 5–10 yr and 158 were from 10–15 yr age group of
children. Microscopy remains the main diagnostic tool
followed by RDK in all the studied districts (Fig. 2).
Amongst the diagnosed cases (91.6%) which were either
diagnosed microscopically (86.1%) or with RDK or both
(13.9%), 26.2% were positive for malaria while others
were negative (72.5%) and results were unknown in 1.3%
cases as conclusions could not be made even after the
diagnosis (Fig. 3). Furthermore, amongst the confirmed
P. falciparum cases (26.2%), ACT prescription was
documented in only 3.4% of cases while others were
either treated with non-artesunate treatment (NA = 96.2%)
which includes chloroquine alone, chloroquine with
PQ/other drugs, SP alone or SP with other drugs
Fig. 2: District-wise diagnostic practices as evident from exit inter-
views, Jharkhand, India 2009.
Fig. 3: Flow chart of patient case management from exit interviews, Jharkhand, India, 2009. NA — Non-artesunate treatment; AM—Artesunate
monotherapy; ACT (WHO) or ACT (non-WHO)—Artemisinin-based combination therapy WHO recommended or Artemisinin-based
combination therapy other than WHO recommended; NM—Non-antimalarial. 275 Mishra et al: Antimalarial prescription practices in children
(Table 1). Artemisinin monotherapy (AM) treatment was
prevalent in 6.6% of diagnosed cases while others in the
diagnosed category were treated with non-antimalarial
(NM = 2.6%) in both malaria positive (0.3%) and
malaria negative (2.3%) category. Amongst the undiag-
nosed cases (8.4%), patients were either given non-
artesunate treatment (7.4%) or artemisinin monotherapy
(0.8%). ACT prescription was also documented amongst
the undiagnosed cases although at a low prevalence
of 0.3% but still holds statistical significance (p <0.05)
when compared with diagnosed cases (Fig. 3).
Availability of blister packs and ACT prescription
Attempts were made to understand if availability of
blister packs is affecting ACT prescription and if at all
there exists any correlation. The availability of ACT blis-
ter packs was confirmed in three out of the five districts,
namely Ranchi, Simdega and Latehar. Although the total
prevalence of ACT prescription was very low (n=18) but
still it was confirmed only in the above mentioned three
districts (Fig. 4). Also ACT prescription was strongly
associated with the availability of ACT blister packs at
the health facilities as the calculated value of chi-square
(χ2=7.10) was found to be significant (3.841 at 1 d.f.) at
5% level of significance.
DISCUSSION
The change in national drug policy of India led to the
implementation of ACT in chloroquine resistant areas. In
the year 2008, 12 districts of Jharkhand were identified as
chloroquine resistant but the availability of ACT was con-
firmed by only five of them. Furthermore, translation of
changed drug policy to its implementation could not be
confirmed to a great extent as ACT prescription was very
low. The unavailability of blister packs for children aged
≤15 yr was another reason which led physicians to pre-
scribe inappropriate drugs and made implementation of
ACT even more difficult. Moreover, physicians prescribed
presumptive treatment of malaria with unjustifiable use
of antimalarial drugs and antibiotics suggesting prevalence
of irrational treatment practices as documented earlier23.
Both retrospective (audit of records) and prospective
(exit interview) data analyses were suggestive of non-
implementation of recently introduced ACT although use
of diagnosis improved within this period with 91.6% of
patients being diagnosed during the period of exit data
collection as compared to 16.9% suggested by audit of
records. Antimalarial prescription was prevalent both in
undiagnosed category and malaria negative category
which exhort unregulated treatment practices. ACT pre-
scription was very low with only 4 and 3.4% as per audit
of records and exit interview respectively, again signify-
ing non-acceptance of newly changed drug policy.
Furthermore, for effective implementation of changed
drug policy it is necessary to adopt few measures like
provision of basic infrastructure for diagnosis with avail-
ability of newly introduced drug and withdrawal of obso-
lete therapy from the market. Awareness amongst the
physicians and the general community in terms of con-
ducting basic training programmes and campaigns is an-
other pre-requisite for regulated use of antimalarials and
effective malaria case management.
Table 1. Antimalarial groups and treatment prescribed to patients
from exit interviews, India 2009
Drug group/treatment n % PQ* Abx** PCM†/
Other drugs
Artemisinin monotherapy 41 6.3 15 24
Non-artesunate treatment 587 88.1 108 361 452
Chloroquine 554 108 332 429
Primaquine 30 29 21
Sulphadoxine-pyrimethamine 3 2
ACT (WHO) 18 2.6 5 14
ACT 9 2 7
SP+ACT 9 3 7
ACT (non-WHO) 4 0.6 1 1 3
CQ+Arteether/Artemether/ 4 1 1 3
Artesunate
Non-antimalarial drug 16 2.4   8 13
*Primaquine; **Antibiotics; †Paracetamol.
Fig. 4: District-wise treatment practices as evident from exit
interviews, Jharkhand, India, 2009 [NA – Non-artesunate
treatment; AM–Artesunate monotherapy; ACT (WHO) or ACT
(non-WHO); NM–Non-antimalarial]. J Vector Borne Dis 50, December 2013 276
CONCLUSION
The study has helped to generate important informa-
tion on the prevailing antimalarial drug prescription prac-
tices in children and the implementation of recently in-
troduced ACT drugs in selected five districts. The study
revealed that the physicians were less inclined to refer
the laboratory diagnosis before prescribing antimalarial
drugs. Awareness among the physicians and other health
personnel for the use of ACT drugs needs to be created
through adequate training. The use of ACT drugs for con-
firmed malaria cases is nominal. More health facility sur-
veys are needed to understand the prevailing prescription
practices and adoption of ACT in the community. Since,
inappropriate use of drugs is known to increase drug pres-
sure and so the development of drug resistance, there-
fore, this study also augments the prospects of studying
drug resistance in these areas as the results suggest them
to be more prone to threat.
Limitations
This study was carried out during 2008 at the time
when ACT was initially implemented in the studied state
and age-specific blister packs were also unavailable at
the PHCs. Availability of loose tablets of artesunate and
sulphadoxine-pyrimethamine was also limited at selected
PHCs. This could have influenced the study results;
however, as this study was a public health need, study
provided evidence for the requirement of age-specific
blister packs in the country and thereafter, the national
programme has introduced age-specific blister packs
throughout the country in 2010. Following this, there
could be improved availability, however, the progress
needs to be monitored from time to time to assess the
availability across the facilities studied as well as in the
larger areas in the country.
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